Previous animal studies conducted in our laboratory have shown that tumor antigen-pulsed dendritic cells (TP-DC) can mediate antitumor effects in vivo. However, durable and complete regression of established tumors has been difficult to achieve through the administration of TP-DC alone. To better augment immune priming to tumors in vivo, we have hypothesized that it is necessary to achieve an increased number of host-derived, naïve T cells at the site of TP-DC vaccine injections. To accomplish this goal, we have embarked on a series of studies that utilize defined chemokines. One of these molecules, secondary lymphoid tissue chemokine (SLC), has been shown to be uniquely chemoattractant for naïve T cells and dendritic cells. We propose that gene modification of DC-based tumor vaccines to produce human SLC will enhance T-cell recruitment and immune priming to tumorassociated antigens, and thereby translate into improved antitumor vaccine efficacy in vivo. Utilizing an E1-, E3-deleted adenoviral vector containing the gene for human SLC, we have been able to transduce human DC to produce biologically active human SLC that chemoattracts human T cells in vitro. SLC production by transduced DC was markedly enhanced upon DC maturation. Additionally, these SLC-secreting DC were found to be viable to a large extent despite the cytopathic effect inherent in adenoviral gene transfer and, most importantly, functional as determined by their ability to prime autologous T cells to a known melanomaassociated antigen, MART-1. Based on these encouraging results, we plan to initiate Phase I clinical studies utilizing DC-SLC to treat patients with advanced solid tumors.
A lthough animal studies have shown that tumor antigen-pulsed dendritic cell (TP-DC)-based vaccines can mediate antitumor effects in vivo, human clinical trials utilizing this strategy for the treatment of advanced malignancies have thus far had only modest results. A limitation associated with this immunization approach is that subcutaneously/intradermally injected TP-DC fail to migrate efficiently to secondary lymphoid organs; it is there that they encounter naı¨ve T cells, which is a critical step for the initiation of a primary immune response. In order to achieve increased antitumor efficacy in vivo, we have sought to eliminate the need for efficient lymph node trafficking of ex vivo generated DC by bringing host-derived naı¨ve T cells to the site of injection.
Over the past few years, there has been growing interest in chemokines within the field of tumor immunology and immunotherapy. Chemokines are small protein molecules that are involved in immune and inflammatory responses in that they direct leukocyte trafficking to areas of injury as well as to locations where primary immune responses are initiated (ie secondary lymphoid tissues such as lymph nodes, spleen, Peyer's patches, and tonsils). [1] [2] [3] To date, there are four classes of chemokine molecules (C, CC, CXC, and CX 3 C), which are named for the number and location of cysteine residues on the amino terminus of the protein. 3 These molecules communicate with their target cells via G-protein-coupled receptors that are pertussis toxin sensitive. 3 Different chemokines act on different leukocyte populations, thereby modulating the influx of immune effector cells to the area in question based on the needs of the particular situation. Early work investigating the idea of using chemokines to induce antitumor immunity involved stably gene-transducing tumors to produce chemokines. For example, antitumor immunity was successfully generated in vivo when tumors were transduced to produce RANTES, a CC chemokine. This effect was attributable, at least partially, to the recruitment of effector T cells to the tumor site. 4, 5 Similar effects of effector lymphocyte recruitment have been seen using Mig (CXCL9) and Lymphotactin (XCL1). 4 4 A shortcoming of this approach, however, is that it relies on migration of effector cells to the tumor site in order to initiate an antitumor response which assumes that the tumor-bearing host already harbors large numbers of circulating effector cells.
In an effort to improve the efficacy of tumor vaccines, several investigators have explored the use of gene therapy to impart cytokine or tumor antigen production capability on DC. [6] [7] [8] These efforts have focused on enhancing tumor antigen presentation and loading by DC as well as subsequent T-cell activation and expansion. We have sought to improve vaccine efficacy through increased colocalization of DC with naı¨ve T cells, as the process of migration of DC to draining lymph nodes (DLN) for initiation of an immune response occurs inefficiently. Recently, interest has developed in secondary lymphoid tissue chemokine (SLC; also known as CCL21, Exodus-2, thymus-derived chemotactic agent 4, 6CKine), which is a CC chemokine found in the high endothelial venules of lymph nodes. SLC is unique in that it is a chemokine that is a selective chemoattractant for naı¨ve T lymphocytes and mature dendritic cells. 2, 3 We hypothesized that transducing DC with a gene encoding for SLC would result in increased trafficking of naı¨ve T cells to the site of vaccination, with resultant extranodal T-cell priming, activation, and specific antitumor effects. In the lymph node, SLC is believed to play an important role in the initiation of an immune response by colocalizing naı¨ve T cells with DC-presenting antigen.
In preclinical animal studies, we 9, 10 have used SLC as a treatment for tumors established from the poorly immunogenic B16 melanoma. Intratumoral injection of SLC inhibited tumor growth in a CD8
þ , T-cell-dependent manner. SLC elicited a substantial influx of DC and T cells into the tumor, coincident with the antitumor response. SLC gene-modified DC was then used as a treatment of established tumors. Intratumoral injections of SLC gene-expressing DC resulted in tumor growth inhibition that was significantly better than either control DC or SLC alone. Distal site immunization of tumorbearing mice with SLC gene-modified TP-DC elicited an antitumor response, whereas control DC did not. We also found that s.c. injection of TP-DC expressing SLC promoted the migration of T cells to the immunization site. Direct administration of DC genetically modified to express SLC into growing B16 melanoma could also result in a substantial, sustained influx of T cells within the mass with only a transient increase in T-cell numbers in the DLN. DC was retained at the tumor site with only a very small percentage trafficking to DLN. The T cells infiltrating the tumor mass expressed the activation marker CD25 within 24 hours and developed IFN-g secreting function within 7 days as tumor growth was inhibited. Similar results were obtained in lymphotoxin-a gene knockout mice, which lacked peripheral lymph nodes. Our murine studies demonstrated for the first time that effective T-cell priming could occur extranodally and result in measurable antitumor effects in vivo. Thus, in mice, SLC could both induce antitumor responses and enhance the antitumor immunity elicited by DC. Other examples of the antitumor activity of SLC in vivo have been reported when administered either in recombinant form against two transplanted weakly immunogenic lung cancers and a spontaneous bronchoalveolar cell carcinoma 11, 12 or by a herpes simplex virus amplicon mediating codelivery of SLC and CD40L against the A20 B-cell lymphoma and CT-26 adenocarcinoma. 13 In the present study, we generated DC from peripheral blood mononuclear cells (PBMC) obtained through leukapheresis of healthy human donors. These DC were transduced with an adenoviral vector encoding the gene for human SLC (AdSLC), and studies were performed to determine transduction efficiency and protein production by the transduced DC, as well as to determine the effects of AdSLC infection on DC phenotype and function. The ultimate goal of these experiments is to translate the use of human DC-SLC to the clinical setting for the purpose of treating advanced tumors in patients.
Materials and methods

Culture of human DC
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by leukapheresis, and were cryopreserved in liquid nitrogen until use. Once thawed, PBMC were resuspended in serum-free X-VIVO-15 (Bio-Whittaker, Walkersville, MD) containing penicillin, streptomycin, and 5% human AB serum, and were placed in culture overnight. Nonadherant cells were then removed, and the remaining adherent monocytes were resuspended in X-VIVO-15 medium containing 100 ng/ml GM-CSF (Immunex Corporation, Seattle, WA) and 50 ng/ml IL-4 (Schering Corporation, Kenilworth, NJ). After 6 days of culture, adherent and nonadherent cells were harvested using 3 mM EDTA in PBS with gentle scraping and pooled.
Adenoviruses
AdCMVeGFP.dlE3 and AdCMVpLpALoxP.dl309 (empty construct, Adempty) viruses were obtained as high titer stocks from the University of Michigan Vector Core (www.med.umich.edu/vcore). AdCMVhSLC was constructed by isolation of hSLC cDNA obtained by digestion of pCMVIII-hSLC with EcoRI and XhoI. The hSLC cDNA fragment was then inserted into EcoRI and SalI sites of the Ad5 shuttle vector pACCMVpLpA(À)LoxP-SSP. A full-length E1-, E3-deleted recombinant adenovirus was then generated using in situ loxP recombination between the shuttle vector (linearized with PmeI) and the cAd5-deltaE3.LoxP cosmid containing the Ad5 backbone (linearized with ClaI) in the presence of purified Cre recombinase.
14 The resulting recombinant adenoviral DNA was then transfected into HER 911 cells by standard calcium phosphate precipitation methods. Recombinant clones were identified as plaques in soft agar culture and characterized by dideoxynucleotide sequencing to verify the orientation and identity of the hSLC cDNA prior to further amplification. Large-scale, high-titer adenoviral purification, particle determination (particles/ml), and titer determination (plaque forming units/ml) were performed using Vector Core modifications of established methods. 15 Aliquots of AdCMVeGFP.dlE3, AdCMVpLpALoxP.dl309, and AdCMVhSLC were maintained at À80C until immediately prior to use.
Gene modification of human dendritic cells
Following harvest, DC were resuspended at a concentration of 2 Â 10 7 /ml in X-VIVO-15 medium containing penicillin, streptomycin, and 2% human AB serum (transduction medium). Transduction medium was also dispensed into separate microcentrifuge tubes at a volume of 50 ml per million DC to be transduced. For experiments utilizing cationic liposomes, Lipofectaminet (Invitrogen, Carlsbad, CA) was added to each tube to achieve a concentration of 50 mg/ml. Appropriate quantities of adenovirus were then added to each tube to achieve the desired multiplicity of infection (MOI), and the virustransduction medium mixture was incubated at room temperature for 20 minutes. DC were then added to each transduction medium-virus mixture, and then incubated at 371C for 2 hours, with continuous agitation. Samples were centrifuged and the virus-containing supernatants were carefully removed. Transduced DC were then resuspended in X-VIVO-15 medium containing penicillin, streptomycin, 2% human AB serum, 100 ng/ml GM-CSF, and 50 ng/ml IL-4. For experiments in which DC were matured, 2 ml of 500 Â ''maturation cocktail'' (MC) was added for each ml of medium to achieve a final 1 Â solution of 1000 U/ml IL-6 (PeproTech, Rocky Hill, NJ), 10 ng/ml IL-1b (PeproTech), 10 mg/ml PGE2 (Acros Organics, NJ,), and 10 ng/ml TNFa (R&D Systems, Minneapolis, MN). Untransduced DC were ''mock infected'' in that they were incubated in microcentrifuge tubes in the presence of liposomes for the duration of the transduction period.
Microchemotaxis assay
In total, 600 ml of DC culture supernatant to be tested, or known concentrations of recombinant human SLC (R&D Systems), were placed in 24-well plates in duplicate. Transwell s (Corning Inc., Corning, NY) inserts with 5.0 mm pore size membranes were then placed in each well and 2.5 Â 10 5 T2 cells in 100 ml complete medium were placed in the upper chamber. Plates were incubated at 371C, 5%CO 2 for 2 hours. Transwells were removed and discarded, and 1 Â 10 4 15 mm polystyrene beads were added to each well. The contents of each well were harvested, washed in PBS, fixed with 2% paraformaldehyde, and quantitated using fluorescence-activated cell sorter analysis. The total number of migrating cells per sample was calculated using the formula: (cell count/bead count) times 1 Â 10 4 . Percent migration was determined by dividing the total migrating cell count per well by the average number of cells in the input chamber (to which responder cells were added without the transwell membrane). The average percent migration calculated from duplicate standard samples was used to construct a standard curve from which SLC concentrations in the unknown samples were extrapolated using nonlinear regression using GraphPad Prism software.
Phagocytosis assay
DC were placed in 24-well plates at a density of 5 Â 10 5 DC per well, in triplicate. To each well, 43 200 MW FITC-Dextran (Sigma Chemical Company, St Louis, MO) was added to achieve a concentration of 1 mg/ml. Plates were placed at 37 or 41C for 2 hours after which cells were washed four times with large volumes of PBS, fixed using 2% paraformaldehyde, and assayed for mean fluorescence intensity using fluorescence-activated cell sorter analysis.
Fluorescence-activated cell sorter analysis
Antibodies were purchased from PharMingen (San Diego, CA), except for anti-human CD83 that was obtained from Immunotech (Marsielle, France); samples were analyzed using Becton-Dickinson equipment and CellQuest software. The population of DC being studied was identified using forward and side scatter characteristics, upon which the initial gate was set. To determine transduction efficiency of AdGFP-transduced DC, a second gate was designed to exclude the 7-AAD-negative (nonviable) cell population, and the percentage of cells expressing GFP was determined using histogram plots of the AdGFP-infected cell samples as compared to uninfected controls. FITC-labeled antibodies to human CD1a, CD14, CD80, CD83, CD86, HLA-DR, and Cy-chromelabeled anti-human CD11c were used to determine DC phenotype under untransduced, transduced, mature, and immature conditions. The percentage of positive cells was determined in relation to the isotype control for each antibody. For the phagocytosis assays, particle uptake was determined by measuring the mean fluorescence intensity of each sample.
ELISA
ELISAs were performed using the Quantikine s human 6Ckine/CCL21 Immunoassay kit (R&D Systems) according to the manufacturer's protocol.
In vitro T-cell stimulations
Following gene modification, HLA-0201-positive DC were placed in culture in serum-free X-VIVO-15 media supplemented with penicillin, streptomycin, GM-CSF, IL-4, and maturation cocktail as described above. After 24 hours, they were pulsed with MART-1 (ELAGI-GILTV, 26-35) peptide (Invitrogen) at a concentration of 10 mg/ml. At 48 hours following infection, the cells were washed and then combined with autologous, nylon-woolenriched T cells at a DC:T-cell ratio of approximately 1:10 in serum-free X-VIVO-15 medium supplemented to contain 10 IU/ml IL-2 (Chiron Corporation, Emeryville, CA) and 10 ng/ml IL-7 (PeproTech, Rocky Hill, NJ). The DC and T cells were cocultured for 1 week, following which the T cells were harvested and restimulated again as above.
Tetramer staining
Following two or three stimulations by autologous MART-1-pulsed DC, T cells were harvested, counted, and stained using anti-human CD19, CD13, and CD4 antibodies as well as 7-AAD purchased from PharMingen (San Diego, CA) and the iTAGt MHC tetramer: HLA-0201 Melanoma MART-1(ELAGIGILTV)-PE/CD8-FITC (Beckman-Coulter Inc., San Diego, CA). FACS analysis was performed as described previously. Sequential gating was performed to exclude CD4, CD19, CD13, and nonviable (7-AAD positive) cells; an additional gate was used to specifically target the CD8-positive cell population. Double-positive (CD8-FITC and tetramer-PE) cells were considered to be MART-1 specific.
Results
Optimization of adenoviral-mediated gene transfer into human DC
In order to optimize the conditions for adenoviral transduction, DC were first transduced with AdGFP. At 48 hours following infection, cells were harvested and counterstained with 7-AAD in order to exclude nonviable cells, and FACS analysis was performed (Fig 1) . Simple coincubation of DC with adenovirus at a MOI of 1 Â 10 4 viral particles per cell, the ''standard protocol'', resulted in consistently low levels of GFP expression (21.37%) at 48 hours after infection. In order to significantly increase transgene expression using this protocol, the MOI had to be increased to over 1 Â 10 5 viral particles per cell, which carried with it unacceptable cytopathic effects (not shown). GFP expression at 48 h after infection was found to substantially increase, both with the use of cationic liposomes (Lipofectaminet) and with the addition of maturation cocktail (MC) following infection, to levels of 29.17 and 29.11%, respectively. Using a combination of cationic liposomes during transduction along with postinfection maturation of the infected DC yielded the greatest GFP expression, 58.92%. The pattern of increased GFP expression with the use of liposomes, MC, or the combination of the two factors was found to be consistently reproduced over a wide range of MOI (not shown).
Quantitation of SLC production by transduced human DC
Supernatants taken from DC 48 hours following infection with AdSLC at an MOI of 1 Â 10 4 viral particles per cell were assayed for SLC content by ELISA. One million DC-SLC generated from three different donors were found to consistently produce in excess of 150 ng/ml of SLC in a 48 hours period (Fig 2) . In contrast, mockinfected or empty virus-infected DC generated less than 9.9 pg/ml per sample (data not shown). Some degree of donor to donor and/or infection to infection variability ) that revealed increasing GFP expression with increasing MOI for each of the four separate conditions tested (data not shown).
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exists, however, as two donors (#3 and #5) demonstrated significantly lower levels of SLC protein production by DC-SLC. In order to determine whether or not SLC protein secreted by DC-SLC is functional, supernatants taken from 1 Â 10 6 DC-SLC were placed in the bottom chamber of a microchemotaxis assay, and allowed to induce migration of T2 cells via a porous membrane. SLC concentrations within these samples were extrapolated from a standard curve generated from the migration of T2 cells in response to known concentrations of recombinant human SLC, as described previously. SLC concentrations within DC-SLC supernatants determined by this method were found to range from 9.974.5 ng/ml for DC-SLC infected at 5 Â 10 3 particles per cell to 155.8726.2 ng/ml for those infected at 4 Â 10 4 particles per cell (expressed as mean7SEM, Fig 3a) . In contrast, supernatants from uninfected DC induced no additional T2 cell migration over background (media alone), resulting in a calculated SLC concentration of zero. As shown in (Fig 3b) , supernatants from DC-SLC transduced at 1 Â 10 4 particles per cell induced much greater SLC production than uninfected DC, or DC infected with the empty adenoviral construct, each of which exhibited chemotactic activity of a level comparable to media alone. The presence of an additional, yet uncharacterized chemotactic factor(s) being present in DC-SLC supernatants is unlikely as the SLC concentration determined through the microchemotaxis bioassay is consistently lower than that determined by ELISA in side-by-side experiments (data not shown). However, the presence of an inhibitory factor cannot be excluded, as the converse has not been found to be true.
Effects of adenoviral gene modification on DC viability
As illustrated in (Fig 4) , the viability of DC infected by adenovirus at an MOI of 1 Â 10 4 viral particles per cell (in the presence of cationic liposomes and subsequent maturation) was decreased as compared to untransduced controls. However, this result is both expected and modest, with the numbers of viable transduced DC approximately 75% of control DC carried out to 4 days following infection. 
Effects of adenoviral gene modification on DC phenotype
The phenotype of the monocyte-derived DC was considered to be immature, with low percentages of cells expressing CD1a, CD14, CD80, and CD83 (Fig 5) . Regardless of maturation or adenoviral infection, these DC are uniformly positive for CD86, MHC-Class II, and CD11c. Striking differences were noted in CD80 and CD83 expression with or without the addition of maturation cocktail, indicative of the maturation process. To a lesser exent, adenoviral infection in and of itself was found to induce DC maturation as evidenced by increased levels of CD80 and CD83 in the population of cells that were transduced but not treated with maturation cocktail.
Effects of adenoviral gene modification on DC function
To determine whether or not DC function was negatively impacted by adenoviral infection, we tested two key DC functions: the ability to prime naı¨ve T cells in vitro, and the capacity to phagocytose particulate material. To determine whether DC-SLC can prime naı¨ve T cells in vitro to the same extent as untransduced DC, DC were matured, pulsed with MART-1 peptide, and then used to stimulate autologous, nylon-wool-enriched T lymphocytes. Following two or three sequential stimulations by DC, MART-1 tetramer staining was performed. As shown, DC-SLC were able to prime naı¨ve T cells to at least the same extent as DC alone (Fig 6) . No significant difference in T-cell priming capability was seen between AdSLC-transduced DC and Adempty-transduced DC in replicate experiments (data not shown). As this experiment utilized a defined peptide, it did not require active uptake and processing of tumor antigens by the DC. To test whether phagocytic capability remained intact following adenoviral infection, DC were fed FITC-labeled dextran particles 24 hours following infection7matura-tion with the addition of MC to the media. Untransduced, immature DC were found to robustly take up FITCdextran as evidenced by a high fluorescence intensity by FACS analysis. While adenoviral infection alone did not have a significant impact on particulate uptake by DC (P ¼ 0.2442 by a two-tailed, paired t-test), maturation clearly did impair DC phagocytic capability, with fluorescence intensity approaching control (41C) levels (Fig 7) .
Discussion
Through the experiments performed here, we have accomplished successful infection of human monocytederived DC with Ad-SLC, with resultant functional SLC protein production and preservation of DC function. In our hands, however, the successful use of an adenoviral vector to transduce DC has required the help of an additional agent, namely cationic liposomes. Regarded as a difficult-to-transduce cell type, DC have been transduced with varying success using a variety of viral and nonviral vectors. As demonstrated by Arthur et al 16 , adenoviral-mediated gene transfer is much more efficient than nonviral methods such as plasmid DNA transfer with various cationic liposome preparations, electroporation, or CaPO 4 co-precipitation. However, as DC lack the Coxsackie B and adenovirus receptor (CAR), the process of attachment of the virus to the DC cell membrane is suboptimal, thus making infection rather difficult. Other groups have sought ways around this obstacle, including increasing the contact between the virus and the cell membrane through centrifugation, 8 or utilizing small volumes for transfection. 17 While it has difficulty attaching to the cell membrane, a particular advantage of adenovirus is in its action as an endosomal disruption agent. Liposomes, on the other hand, are popular nonviral vectors that function through charge-mediated binding of liposome-DNA complexes to the negatively charged cell membrane. Release of the liposome-DNA complex from the endosome is an inefficient process, however. Adenovirus has previously been combined with cationic liposomes in a successful effort to transduce a cell type lacking CAR, seeking to take advantage of the different yet complementary properties of the two vectors. 18 Based on this study and another report 19 of the use of the combination of cationic liposomes with adenoviral vectors to transduce DC, we utilized this approach with similar success. As our goal was to achieve the highest level of SLC protein production possible, and because maturation of DC elicits upregulation of the expression and translation of a variety of genes, we tested the capacity of an MC to both elicit DC maturation as well as to induce greater transgene expression. The maturation cocktail used in our experiments was based on the key factors present in monocyte-conditioned medium, plus the addition of PGE 2 as described by 
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Jonuleit et al 20 As demonstrated in Figure 1 , use of AdSLC in the presence of cationic liposomes, with subsequent maturation of the DC resulted in the greatest transgene expression at each of the various MOI tested.
Once the conditions for infection were optimized using AdGFP, our attention was turned to the AdSLC virus. We settled on an MOI of 1 Â 10 4 particles per cell in an effort to strike a balance between gene expression and cytopathic effect. Using AdSLC at this MOI, in combination with liposomes and maturation, DC-SLC were generated and were found to produce in excess of 150 ng/10 6 cells in a 48 hours period. While this was true for three of the five donor DC that were tested, two other donors exhibited detectable, but significantly lower levels of SLC production. The possible reason(s) for this finding is unclear at this time. However, upon translation of this treatment strategy to the clinical setting, the variations in SLC production will likely not have a significant effect on in vivo efficacy. In a C57BL/6 murine model of DC-SLC vaccination for the treatment of established B16-BL6 tumors, Kirk et al 10 demonstrated that as little as 750 ng of SLC (as produced by 5 Â 10 5 DC-SLC administered twice) can elicit a measurable, statistically significant antitumor effect. For our planned clinical protocols, patients will receive 1 Â 10 8 DC-SLC per treatment. This dose level will allow for a minimum of 850 ng of SLC to be delivered per dose in a case in which, such as donor #3 in Figure 2 , 1 Â 10 6 DC-SLC only produce 8.5 ng/ml of SLC by ELISA. Not only is this sufficient to produce a measurable effect based on the evidence reported by Kirk et al, but it is much more likely that quantities of SLC approaching 15-25 mg/dose will be delivered to patients receiving 1 Â 10 8 DC-SLC. The ability of adenoviral infection to cause maturation of DC is well described, and was reproduced in our experiments as well. We believe that this is a desirable side effect of adenovirus-mediated gene modification as mature DC express high levels of the surface costimulatory molecules necessary for delivery of the second signal to T cells leading to antigen-specific activation and proliferation. The issue that arises, however, is how to best load DC-SLC with antigen. As we have shown through our phagocytosis assays, DC-SLC that have not been further matured using a cytokine cocktail are able to take up particulate material at a similar level as that of untransduced DC; terminal maturation of DC however, transduced or not, shows a significant reduction in phagocytic capacity. The optimal strategy for loading gene-modified, mature DC with tumor antigen(s) may be through pulsing with known, HLA-restricted, tumorassociated and immunogenic peptides. Using the melanoma-associated peptide MART-1, we were able to demonstrate efficacy of this strategy to prime naı¨ve T cells in vitro. In fact, the percentage of CD8 þ /MART-1 tetramer þ T cells that were generated by DC-SLC was shown in some instances to be greater than those produced by unmodified DC. Although we cannot currently draw conclusions as to whether this is a chance occurrence or due to a real effect of SLC that is distinct from its chemoattractant function, studies are ongoing to resolve this issue. Additionally, while an increase in the numbers of CD8 þ /MART-1 tetramer þ T cells generated by MART-1 pulsed DC-SLC is potentially an important finding, this will need to be followed up with functional studies, including cytokine release and ELISpot assays.
Well accepted disadvantages to the use of peptideloaded DC for the treatment of cancer patients include the requirement for the tumor-associated peptide antigens to be known, and for the patient to be of a particular HLA type. These facts limit the use of this particular vaccine strategy. A more broadly applicable method utilizes the loading of DC with tumor antigens through pulsing with autologous (or allogeneic) killed tumor cells or lysates, or through direct intratumoral administration of the DC to allow for tumor antigen uptake from within the tumor microenvironment. While we aim to utilize mature DC for reasons stated previously, the mature state of DC inhibits uptake of antigens present intratumorally or within a killed tumor preparation. To optimize antigen loading through pulsing with the latter tumor antigen form, logical strategies may be to pulse with the killed tumor preparation prior to adenoviral infection, or after infection but before maturation with a cytokine cocktail. Optimization of the intratumoral strategy may be more complex however, and may require that the DC-SLC be administered without further maturation, or followed by intratumoral injection of proinflammatory cytokines to cause maturation after antigen loading is well underway.
The next natural step to determine whether or not SLC gene modification of human DC vaccines results in enhancement of antitumor immunity in vivo will be through the performance of a series of clinical trials. Through a phase I trial involving patients with advanced cancers, we plan to evaluate the toxicity and the immunological response to autologous whole tumor lysate-pulsed DC-SLC vaccines, as well as to observe these patients for evidence of clinical antitumor responses. Following the demonstration of the safety and feasibility of this approach, plans are in place to test the clinical efficacy of autologous whole tumor lysate-pulsed DC-SLC vaccines in a phase II trial involving patients with advanced melanoma. Short of bringing this strategy to the clinic, experiments were attempted in which human DC-SLC were administered intratumorally into human melanoma xenografts implanted subcutaneously into immunodeficient mice, concurrently with the adoptive transfer of naı¨ve human T lymphocytes. Owing to the inherent technical and biologic limitations of this experimental model, including difficulties with reconstitution of a human immune system in a mouse as well as questions as to whether trafficking of adoptively transferred human lymphocytes actually occurs across murine vasculature, 21 we were unable to generate interpretable results when comparing DC-SLC vs. DC alone in this model.
In summary, we have successfully implemented a combination viral/nonviral vector for the purposes of highly efficient gene modification of human, monocytederived DC. Significant quantities of functional SLC protein were shown to be elaborated, with preservation of DC viability and function. While peptide loading of gene-modified, mature DC seem to be the optimal vaccine approach, ongoing studies will attempt to work out the most suitable strategy for performing tumor lysate pulsing and/or intatumoral injection in combination with gene modification and proinflammatory cytokine-mediated DC maturation. Plans are currently underway to bring DC-SLC to the clinic within the context of phase I/II clinical trials for the treatment of advanced melanoma.
